
AstraZeneca's Q2 earnings jump 21% despite generic drug competition, beating estimates.
AstraZeneca reported a 21% increase in core earnings per share to $2.63 for Q2 2026, surpassing analyst expectations of $2.50. Total revenue rose 6% to $15.38 billion, driven by strong sales in oncology and rare disease drugs, offsetting pressure fro...
